Gem Aromatics repeats its FY28 guidance. The transcript adds nothing.
The full Q4 earnings call transcript reiterates the ₹1,050-1,100 cr revenue target and 16-18% EBITDA margin. No new information is disclosed.
— 4 earlier stories on Gem Aromatics Ltd. →What's new
- The transcript is a verbatim Q&A of the prior concall summary.
- It repeats the Dahej facility ramp-up and phenol derivative delay discussions.
- No new financial data, order wins, or strategic shifts are disclosed.
Why this matters
This is a compliance release, not a news event. The full transcript adds detail to the Q&A but no substance. The market already priced the guidance when the summary dropped.
What we're watching
- Dahej facility commissioning progress versus management's sketched timeline.
- Quarterly revenue run-rate toward the ₹1,050-1,100 cr target.
- Any update on phenol derivative delays impacting the 16-18% margin band.
The full read
Gem Aromatics' Q4 earnings transcript is a formality. It repeats the ₹1,050-1,100 crore FY28 revenue target and the 16-18% EBITDA margin. The Dahej facility ramp-up and phenol derivative delays were discussed again. Nothing new. The rationale confirms the transcript contains no material new information beyond the prior concall summary. This is a regulatory filing, not a catalyst. For a stock that already reacted to the initial guidance, this is a non-event. The only forward item is whether the Dahej ramp hits the timeline management has sketched.
Questions answered
- What is the core guidance reiterated in this transcript?
- Gem Aromatics targets ₹1,050-1,100 crore in revenue for FY28 with a 16-18% EBITDA margin. This is unchanged from the earlier concall summary.
- Does this transcript contain any material new information?
- No. The rationale explicitly states the transcript contains no material new information beyond the prior summary, providing only the detailed Q&A without new numbers or timelines.
- What is the status of the Dahej facility ramp-up?
- The facility is in a ramp-up phase, but the transcript provides no new commissioning date or production milestone beyond what was already disclosed.
- Why are phenol derivatives mentioned in the context of margins?
- The delays in phenol derivatives are a factor behind the 16-18% EBITDA margin guidance range. The transcript did not add new context to this known issue.
Gem Aromatics Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on GEMAROMA →- 26 May 2026 · 4:22 PM IST Gem Aromatics repeats its FY28 guidance. The transcript adds nothing.
- today Gem Aromatics sets up Brazil subsidiary, commits up to ₹17 cr
- 32d ago Gem Aromatics targets ₹1,100 cr revenue by FY28 on Dahej ramp
- 33d ago Gem Aromatics files the same Q4 results again. Nothing is new.
- 33d ago Gem Aromatics profit falls 97% in FY26; directors waive pay